Recent studies have shown that the inhibition of casein kinase 2 (CK2) sensitizes many cancer cells to Fas ligand-and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. However, it has not been demonstrated directly whether CK2 inhibition can also enhance the cytotoxicity of natural killer (NK) cells, which actually use the death ligands to kill cancer cells in vivo. To address whether NK cell-mediated cancer cell death is affected by the inhibition of CK2, we first checked whether the death ligandinduced apoptosis of hepatocellular carcinoma cells (HCCs) and HeLa were affected by CK2 inhibition. We then investigated the effect of CK2 inhibition on NK cytotoxicity against HCCs and HeLa cells and its mechanistic features. Inhibition of CK2 by emodin increased the apoptotic cell death of HepG2, Hep3B and HeLa when the cancer cell lines were treated with a soluble form of recombinant TRAIL or an agonistic antibody of Fas. This phenomenon appeared to be correlated with the expression level of death receptors on the cancer cell surface. More interestingly, the inhibition of CK2 also greatly increased the NK cell-mediated cancer cell killing. The NK cytotoxicity against the cancer cells increased about twofold when the target cells were pretreated with a specific CK2 inhibitor, emodin or 4,5,6,7-tetrabromobenzotriazole. Furthermore, the increase of the NK cytotoxicity against cancer cells by CK2 inhibition was granule-independent and mediated possibly by the death ligands on the NK cell surface. This suggests that CK2 inhibitors could be used to enhance the cytotoxicity of NK cells and consequently increase host tumour immunity.
Introduction
Natural killer (NK) cells are a distinct subset of large granular lymphocytes, which possess the ability to kill certain primary tumour cells, tumour cell lines, virus-infected cells and transplanted allogenic cells. NK cells are able to lyse target cells spontaneously without the need for specific antigen recognition or prior sensitization [1, 2] . In particular, NK cells are believed to play important roles in tumour immunity [3] . It is well known that NK cells kill many leukaemia cells effectively [2, 4] , and more recent studies have demonstrated that NK cells can destroy many solid tissuederived malignant cells, such as melanoma, breast cancer, lung cancer, gastric cancer, colon cancer, renal cancer, ovarian cancer and hepatoma cell lines [5] [6] [7] [8] .
Two major pathways are involved in the killing mechanism of NK cells, just as in the case of cytotoxic T cells. One pathway involves a polarized secretion of preformed perforin and granzymes by NK cell granule exocytosis, which leads to rapid caspase activation in target cells, as well as a caspase-independent death pathway [4, [9] [10] [11] [12] . Perforin can induce necrosis of target cells and granzymes can induce apoptosis of target cells [9, 10, 13] . In another pathway, death receptors on target cells are cross-linked by NK cells' death ligands and these interactions trigger a relatively well-studied apoptotic death pathway [5, 6, 14, 15] . The non-secretory/apoptotic pathway is mediated by the Fas ligand (FasL)/Fas, tumour necrosis factor (TNF)/TNF receptor and TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor interactions, which trigger a cell death pathway involving caspase activation [5, 6, 8, [14] [15] [16] [17] [18] .
Death ligands expressed on killer cells induce apoptosis of target cells in vivo, but it is well known that soluble forms of TRAIL or agonistic anti-Fas antibodies can also induce the apoptotic cell death of certain cancer cells [19, 20] . However, many cancer cells are resistant to the soluble forms of TRAIL-and/or FasL-induced apoptosis, although most of them express death receptors on the surface [21, 22] . In particular, most hepatocellular carcinoma cells (HCCs) are resistant to death receptor-mediated apoptosis when the cell surface death receptor is cross-linked in vitro with either agonistic antibodies or soluble forms of death ligand proteins [22] [23] [24] [25] [26] [27] [28] .
Casein kinase 2 (CK2) is a serine/threonine protein kinase [29, 30] which plays a key role in cell cycle control, cellular differentiation and proliferation [31] [32] [33] . CK2 also participates in the regulation of apoptosis by phosphorylating some apoptosis-related factors [21, [34] [35] [36] . Interestingly, CK2 has been found to be up-regulated in many cancer cells [37] [38] [39] . Increased expression of CK2 protects cells from Fas-and drug-induced apoptosis, suggesting that CK2 may have a general anti-apoptotic function [36, 40] . Recent studies have shown that the inhibition of CK2 sensitizes many cancer cells, such as rhabdomyosarcoma, colon carcinoma, breast cancer, cervical cancer and gastric cancer to FasL-and TRAIL-induced apoptosis [21, 36, [41] [42] [43] . However, it has not been demonstrated directly whether CK2 inhibition can also enhance the cytotoxicity of killer cells, which actually use the death ligands to kill cancer cells in vivo.
In a previous report, we demonstrated that NK cells can effectively kill HCCs using the granule-dependent necrotic pathway and the death ligand-dependent apoptotic pathway [8] . In this study, we addressed whether NK cell-mediated cancer cell death is affected by the inhibition of CK2 in target cells. We first checked whether the death ligand-induced apoptosis of HCCs and HeLa were affected by CK2 inhibition. Then, we investigated the effect of CK2 inhibition on NK cytotoxicity against HCCs and HeLa cells and its mechanistic features.
Materials and methods

Natural killer cell preparation
Natural killer cells were purified from the whole blood of healthy volunteers by negative selection using the RosetteSep™ NK enrichment antibody cocktail (StemCell Technologies Inc., Vancouver, Canada), as described previously [8] . Briefly, 1 ml of whole blood was mixed with 50 ml of RosetteSep™ NK enrichment cocktail and incubated for 20 min at room temperature. The blood sample was then diluted with the same volume of phosphate-buffered saline (PBS; pH 7·4) containing 2% of fetal bovine serum (FBS) (Gibco BRL, Grand Island, NY, USA). The diluted sample was layered on the top of Ficoll-Paque (Amersham Pharmacia Biotech, Uppsala, Sweden) and centrifuged for 20 min at room temperature. The NK cell layer was collected and the enriched NK cells were washed three times with PBS containing 2% FBS. Purified NK cells were >80% CD56
-(Beckman Coulter, Fullerton, CA, USA) and were maintained for 2 weeks in RPMI-1640 media containing 10% FBS and 100 units/ml of recombinant interleukin-2 (Endogen, Woburn, MA, USA).
Cell lines and culture
Hepatocellular carcinoma cell lines HepG2 [American Type Culture Collection (ATCC) HB 8065] and Hep3B (ATCC HB 8064) were used as target cell lines and maintained in modified Eagle's medium (MEM) containing 10% FBS (Gibco BRL). HeLa was also cultured in Dulbecco's MEM containing 10% FBS and used as target cells for cytotoxicity assay.
Antibodies and reagents
Anti-Fas antibody (clone CH11), recombinant TRAIL (rTRAIL), emodin and 4,5,6,7-tetrabrombenzotriazole (TBB) were purchased from Medical & Biological Laboratories (Nagoya, Japan), Serotec (Oxford, UK) and Calbiochem (San Diego, CA, USA) respectively. Anti-caspase-3 and antipoly ADP-ribose polymerase (PARP) antibodies were purchased from Cell Signalling Technology (Boston, MA, USA).
Flow cytometric analysis
Cell surface receptors and ligands were quantified by flow cytometric analysis. NK cells and tumour cells were washed twice with ice-cold PBS containing 0·05% bovine serum albumin (BSA). Cells were incubated with phycoerythrinlabelled anti-DR4, anti-DR5, anti-Fas, anti-FasL and anti-TRAIL antibody (Biolegend, San Diego, CA, USA) for 30 min at 4°C. After two washes with 0·05% BSA-PBS, cells were analysed using a fluorescence activated cell sorter (FACScalibur) flow cytometer (BD Bioscience, Franklin Lakes, NJ, USA).
The JAM test (DNA fragmentation assay)
Natural killer cell-mediated apoptotic target cell death was measured using a [ ]-thymidine-labelled target cells were mixed at the indicated effector : tarhet (E : T) ratio. After 2 h of incubation in the presence or absence of the CK2 inhibitor, the cells and their medium were aspirated onto glass fibre filters (size 90 ¥ 120 mm) using a semi-automated 96-well harvester (Tomtec, Hamden, CT, USA). The filters (Wallac Oy, Turku, Finland) were washed, dried and sealed with melt-on scintillator sheets (Wallac) and radioactivity was measured with a beta counter (Wallac). rTRAIL-and CH11-induced cancer cell death was measured similarly using the JAM test. For this assay, target cells were treated with rTRAIL or CH11 for 6 h in the presence or absence of the CK2 inhibitors. Percentage of apoptotic cell death was calculated by the following formula: % DNA fragmentation = [1 -(experimental value/ control value)] ¥ 100. The control value was determined by incubating target cells in culture medium alone.
Lactate dehydrogenase assay
Recombinant TRAIL-and CH11-induced cancer cell death was also assessed by lactate dehydrogenase (LDH) assay using the CytoTox 96 assay kit (Promega, Madison, WI, USA). Target cells, 1 ¥ 10 4 , were prepared in a 96-well microtitre plate and treated as indicated in the figure legends. For the LDH-positive control, 10 ml of lysis solution (10¥) were added to all wells to lyse cells, and the target cells were incubated for 45 min. An aliquot of 50 ml was taken from each well and transferred to a fresh 96-well flatbottomed (enzymetic assay) plate. To each well of the plate, 50 ml of substrate mix was added, and the plate was incubated for 30 min in the dark. After 30 min, 50 ml of stop solution was added to each well and the absorbance was recorded at 490 nm within 1 h using an enzyme-linked immunosorbent assay reader.
Chromium release assay
Natural killer cell-mediated target cell killing was assessed using a standard 51 Cr release assay, as described previously [8] . 
Western blot
Target cells were lysed with a lysis buffer (10 mM Tris-HCL, pH 7·4 150 mM NaCl, 2 mM ethylenediamine tetraacetic acid, 1% Triton X-100, 1 mM phenylmethylsulphonyl fluoride, 15 mg/ml leupeptin, 2 mM NaF, 2 mM NaVO4), and the lysates were separated on sodium dodecyl sulphidepolyacrylamide gels. The protein bands were transferred to polyvinylidene difluoride membranes (Pierce, Rockford, IL, USA). The membranes were blocked with 5% BSA in PBS containing 0·1% Tween-20 (PBST) for 2 h, incubated with proper antibodies for 4 h, and washed with PBST. The membranes were then incubated with peroxidase-conjugated goat anti-mouse IgG (H + l) for 2 h, and washed with PBST. The blots were finally visualized by Supersignal WestDico chemiluminescent substrate (Pierce).
Fixation of NK cells
For blocking granule release, NK cells were incubated for 20 min with RPMI-1640 containing 0·5% paraformaldehyde and washed twice with PBS. The concentration of paraformaldehyde and the incubation time was minimized to avoid adverse effects as much as possible.
Results
Casein kinase 2 inhibitor augments rTRAIL-induced apoptosis of HCCs
In a previous report, we demonstrated that NK cells effectively killed HCCs using the granule-dependent necrotic pathway and the death ligand-dependent apoptotic pathway [8] . Interestingly, recent studies have shown that inhibition of CK2 sensitizes many cancer cells to TRAIL-induced apoptosis [21, 36, [41] [42] [43] . As a first step to investigate the effect of CK2 inhibition on the NK cytotoxicity against HCCs, we checked whether the death ligand-induced apoptosis of HCCs were affected by CK2 inhibition, as it has not yet been demonstrated. For this purpose, HepG2 and Hep3B cell lines were treated for 24 h with emodin, a CK2 inhibitor [45] , in the presence and absence of rTRAIL (10 ng/ml). In order to observe the apoptotic target cell death, the extent of DNA fragmentation was measured using a [ 3 H]-thymidine release assay [44] . As shown in Fig. 1a , rTRAIL or emodin alone induced only limited apoptotic cell death of HepG2 or Hep3B. However, the HepG2 and Hep3B cells exhibited a significant amount of DNA fragmentation when the cells were co-treated with rTRAIL and emodin (Fig. 1a) . Similar phenomena were observed when the target cell death was measured by LDH assay (Fig. 1b) . Emodin or rTRAIL alone induced only limited cell death of HepG2 and Hep3B, but co-treatment of rTRAIL with emodin increases significantly the rTRAIL-induced cell death. Both HepG2 and Hep3B expressed DR5 (TRAIL receptor 2), but not DR4 (TRAIL receptor 1) (Fig. 1c) . As a result, both HepG2 and Hep3B cells were sensitive to rTRAIL-induced apoptosis, and was enhanced in the presence of emodin (Fig. 1a and b) .
We next investigated the dose-dependent effects of rTRAIL and emodin on the apoptosis of HCCs by using the JAM test. As shown in Fig. 2a , apoptotic cell death of HepG2 increased gradually as the amount of emodin increased from 2 to 20 mg/ml in the absence of rTRAIL (black bars, left panel). Furthermore, much greater apoptotic cell death of HepG2 was observed when the amount of emodin was varied from 2 to 20 mg/ml in the presence of a fixed amount of rTRAIL (10 ng/ml; white bars, left panel). The apoptotic cell death of HepG2 increased only slightly when the amount Effect of CK2 inhibition on NK cytotoxicity of rTRAIL increased from 5 to 40 ng/ml in the absence of emodin (black bars, right panel). However, the apoptotic cell death of HepG2 increased substantially as the amount of rTRAIL increased in the presence of the fixed amount of emodin (10 mg/ml; white bars, right panel). Similar dosedependent effects of rTRAIL and emodin were observed when Hep3B cells were treated with emodin or rTRAIL (Fig. 2b, black bars) , and when the cells were co-treated with rTRAIL and emodin (white bars, Fig. 2b ).
Casein kinase 2 inhibition increased the FasL-induced apoptosis of HCCs
We next checked whether the FasL-induced apoptosis of HCCs were also affected by CK2 inhibition. For this purpose, HepG2 and Hep3B cell lines were treated for 24 h with emodin in the presence or absence of an agonistic monoclonal anti-Fas antibody (CH11) [46] . When the amount of cell death was measured by the JAM test, CH11 or emodin alone induced only limited apoptotic cell death of HepG2 and Hep3B (Fig. 3a) . It is well known that HepG2 cells are resistant to FasL-induced apoptosis, although it expresses Fas [22] [23] [24] [25] [26] [27] [28] . However, the HepG2 cells exhibited a significant amount of DNA fragmentation when the cells were co-treated with CH11 and emodin (Fig. 3a, left panel) . Unlike HepG2 cells, Hep3B cells did not express Fas (Fig. 3c) . Consequently, simultaneous treatment of CH11 and emodin did not induce any significant apoptosis in Hep3B cells (Fig. 3a, right panel) . Similar phenomena were observed when the target cell death was measured by LDH assay (Fig. 3b) . CH11 or emodin alone induced only a limited amount of cell death in HepG2 and Hep3B; however, CH11 and emodin co-treatment increased the CH11-induced cell death significantly in HepG2 cells, but not in Hep3B cells.
Effect of CK2 inhibition on death ligand-induced HeLa cell death
We next investigated the effect of CK2 inhibition on death ligand-induced cell death of other tumour cells. A cervical cancer cell line, HeLa, was chosen for this purpose. HeLa cells strongly expressed Fas and DR5, death receptors for FasL and TRAIL respectively (Fig. 4a) . As expected, CK2 inhibition appeared to augment the rTRAIL-and CH11-induced apoptotic cell death of HeLa in the JAM test (Fig. 4b) . Interestingly, we found that HeLa cells were sensitive to emodin treatment. As shown in Fig. 4a , emodin alone induced more apoptotic cell death than rTRAIL or CH11 for unknown reason.
Effects of CK2 inhibition on NK cell-mediated apoptosis
We next investigated the effect of CK2 inhibition on NK cytotoxicity against three cancer cell lines, HepG2, Hep3B and HeLa. In order to observe the apoptotic target cell death mediated by NK cells, the extent of DNA fragmentation was measured by the JAM test, a [ 3 H]-thymidine release assay. When target cells were co-incubated with NK cells for 2 h, Hep3B and HeLa cells exhibited a significant amount of DNA fragmentation, whereas HepG2 cells showed a relatively small amount of DNA fragmentation (Fig. 5a, white bars) . When the target cells were pretreated with emodin and co-incubated with NK cells, all three cancer cell lines exhibited a greatly increased amount of apoptotic cell death (grey bars). Emodin alone induced limited apoptotic cell death only in HepG2 and Hep3B, but for unknown reasons it induced a significant apoptotic cell death in HeLa (black bars).
Similar results were obtained when the NK cells and target cells were co-incubated in the presence of TBB, a more specific CK2 inhibitor [47] . TBB is one of the most efficient inhibitors for CK2, along with 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole [48] . As shown in Fig. 5b , when the target cells were pretreated with TBB and co-incubated with NK cells, all three cancer cell lines exhibited a greatly increased amount of apoptotic cell death (grey bars) as measured by the JAM test. We next investigated the effect of TBB on the necrotic target cell death mediated by NK cells using a 4 h 51 Cr release assay. The standard 4 h 51 Cr release assay is known to measure primarily the necrotic cell death induced by the cytotoxic granules of NK cells [7, 8, 24] . As shown in Fig. 5c and d, NK cells induced necrotic cell death when the target cells were co-incubated with NK cells (white bars). However, treatment of neither emodin nor TBB increased the NK cytotoxicity against the cancer cell lines (grey bars). These results indicated that the inhibition of CK2 of cancer cells augmented the NK cell-mediated apoptotic killing of target cells. The data are presented as a mean of at least three independent experiments (mean Ϯ standard deviation). : rTRAIL or CH11 alone. Effect of CK2 inhibition on NK cytotoxicity
Casein kinase 2 inhibition increases the NK cell-mediated cancer killing by a granule-independent process
In order to investigate whether or not the increase of NK cytotoxicity against cancer cells by CK2 inhibition is granuledependent, NK cells were fixed mildly with 0·5% paraformaldehyde and the cytotoxicities against cancer cells in the presence or absence of CK2 inhibitor were compared. The mild fixation of NK cells or macrophages eliminates the granule release without affecting the structure and function of the cell surface receptors [7, 8, 49] . As reported previously [8] , the fixed NK cells were almost as effective as the untreated NK cells in the JAM test against the HepG2, Hep3B and HeLa cells (Fig. 6, black bars) . When the target cells were pretreated with emodin or TBB and co-incubated with NK cells, all three cancer cell lines exhibited almost the same amount of apoptotic cell death as in the cases of the untreated NK cells (Fig. 6 , white bars and grey bars respectively). In order to confirm the increased apoptotic cell death induced by NK cells in the presence of TBB, caspase-3 and PARP cleavages were examined by immunoblotting (Fig. 6b) . The Western blot analysis shown in Fig. 6b indicated that PARP was more cleaved in TBB-treated HepG2 cells when the cells were co-incubated with NK cells, although caspase-3 cleavage did not appear to be significantly changed. These results suggest that the increase of the NK-mediated apoptotic cancer cell death by CK2 inhibition is granule-independent and mediated possibly by the death ligands on the NK cell surface.
Discussion
Recent studies have shown that increased expression of CK2 protects cancer cells from apoptotic cell death and the inhibition of CK2 sensitizes many cancer cells to death ligandinduced apoptosis [22, 36, [40] [41] [42] [43] . In this study, we demonstrated that HCCs and HeLa cells could also be sensitized to death ligand-induced apoptosis by inhibition of CK2. Inhibition of CK2 by emodin increased the apoptotic cell death of HepG2, Hep3B and HeLa when the cancer cell lines were treated with a soluble form of rTRAIL or an antagonistic antibody of Fas. This phenomenon appeared to be correlated with the expression level of death receptors on the cancer cell surface. More interestingly, inhibition of CK2 also increased greatly the NK cell-mediated cancer cell killing. The NK cytotoxicity against the cancer cells increased about twofold when the target cells were pretreated with a CK2 inhibitor, emodin or TBB. Furthermore, the increase of the NK cytotoxicity against cancer cells by CK2 inhibition was granuleindependent. These results suggest that NK cytotoxicity against cancer cells could be augmented in vivo, as well as in vitro, by inhibition of CK2 using a specific CK2 inhibitor. Unlike normal hepatocytes, most HCCs are resistant to death receptor-mediated apoptosis when the cell surface death receptor is cross-linked in vitro with either agonistic antibodies or soluble forms of death ligand proteins [22] [23] [24] [25] [26] [27] [28] . The resistance of HCCs against death receptor-mediated apoptosis might be an essential step in escaping from host immune surveillance. Interestingly, however, our data showed that HCCs can be sensitized to death ligand-induced apoptosis by inhibiting the CK2 with emodin. CK2 inhibition by emodin appeared to increase rTRAIL-induced cell death significantly in HepG2 and Hep3B (Fig. 1) , as well as increase the agonistic monoclonal anti-Fas antibody (CH11)-induced cell death in HepG2 (Fig. 3) . The death ligand-induced apoptosis was generally proportional to the dose of the CK2 inhibitor (Fig. 2) . Furthermore, death ligand-induced apoptotic cell death in the presence of CK2 inhibitor was also correlated with the death receptor expression level on HCCs. These results suggest that CK2 also plays a critical role in the death receptor-mediated apoptosis of HCCs, as in other cancer cells. It is well known that NK cells effectively kill many leukaemia cells and that the process is mediated primarily by perforin and granzymes [4, [9] [10] [11] . Perforin induces the necrosis of the target cells and granzymes induce the apoptosis of the target cells [15] [16] [17] . More recent studies showed that NK cells can also effectively kill many solid tissuederived tumour cells and that the non-secretory/apoptotic pathway plays a more important role when NK cells eliminate solid tumour cells [7, 8] . The non-secretory/apoptotic pathway is mediated by FasL/Fas, TNF/TNF receptor and TRAIL/TRAIL receptor interactions [5, 6, 8, [14] [15] [16] [17] , and the death receptor-mediated apoptotic pathway is also involved in the cytotoxicity of NK cells against many leukaemia cells [12, 18] . Previously, we showed that NK cells can effectively destroy HCCs, like other solid tumours, and that the death receptor-mediated apoptotic pathway is involved in the NK cell-mediated HCC killing [8] . In this study, we demonstrated that the inhibition of CK2 by emodin or TBB augments NK cytotoxicity against HCCs and HeLa cells in the 2 h [ 3 H]-thymidine release assay ( Fig. 5a and b) , which measures primarily the extent of apoptotic target cell death [7, 8, 24] . Furthermore, we demonstrated that the mildly fixed NK cells are as effective as untreated NK cells in the cytotoxicity against target cells pretreated with emodin or TBB (Fig. 6a) . Because the fixed NK cells cannot secrete the cytotoxic granules, it is highly likely that the increased NK cytotoxicity against cancer cells pretreated with the CK2 inhibitors might be mediated by interactions between death ligands on NK surface and death receptors on cancer cell surface. This is supported further by the fact that the CK2 inhibition of cancer cells did not increase the NK cytotoxicity against these target cells in the 4 h 51 Cr-release assay ( Fig. 5c and d) , which measures primarily necrotic cell death mediated by cytotoxic granules [7, 8, 24] .
Like NK cells, cytotoxic T cells kill target cells by using the secretory cytotoxic granule-mediated pathway and the death receptor-mediated apoptotic pathway [18] . Because the death receptor-mediated apoptotic target cell killing mechanism of cytotoxic T cells is exactly the same as that of NK cells, it is tempting to speculate that the inhibition of CK2 could also enhance cytotoxic T cell-mediated target cell killing. This suggests that CK2 inhibitors could increase the host's innate and adaptive immunity against cancer by enhancing the cytotoxicity of NK cells and cytotoxic T cells which are armed with death ligands.
